Table 1 Relationship between Gal3 expression level and clinical pathological features.
From: Targeting Galectin 3 illuminates its contributions to the pathology of uterine serous carcinoma
Galectin 3 | |||||
|---|---|---|---|---|---|
Total patient number: 37 | Weak (n = 6) | Mod (n = 16) | Strong (n = 15) | p value | |
Age (Median, range) | 63 y.o. (57–83) | 66.5 y.o. (56–84) | 69 y.o. (58–82) | 0.9306 | |
FIGO Stage** | I | 6 | 7 | 4 | 0.0028 |
(n = 37) | II | 0 | 1 | 0 | |
III | 0 | 1 | 6 | ||
IV | 0 | 7 | 5 | ||
Myometrium invasion | <50% | 5 | 8 | 8 | 0.3507 |
(n = 37) | ≥50% | 1 | 8 | 7 | |
LVSI** | Absent | 6 | 7 | 3 | 0.0053 |
(n = 34) | Present | 0 | 7 | 11 | |
Serosal involvement | Absent | 6 | 12 | 10 | 0.2734 |
(n = 37) | Present | 0 | 4 | 5 | |
Cervical involvement* | Absent | 6 | 10 | 5 | 0.0171 |
(n = 37) | Present | 0 | 6 | 10 | |
Ovarian metastasis | Absent | 6 | 11 | 10 | 0.2969 |
(n = 36) | Present | 0 | 5 | 4 | |
Omental metastasis | Absent | 4 | 7 | 8 | 0.1786 |
(n = 30) | Present | 0 | 7 | 4 | |
Pelvic lymph node metastasis** | Absent | 5 | 8 | 3 | 0.0067 |
(n = 26) | Positive | 0 | 2 | 8 | |
Para-aortic lymph node metastasis* | Absent | 3 | 5 | 1 | 0.0332 |
(n = 16) | Positive | 0 | 2 | 5 | |
Distant metastasis | Absent | 6 | 9 | 10 | 0.148 |
(n = 37) | Positive | 0 | 7 | 5 | |
Ascites cytology | Negative | 4 | 7 | 9 | 0.4127 |
(n = 28) | Positive | 1 | 5 | 2 | |
